Medicine and Dentistry
Abdominal Cancer
74%
Achalasia
32%
Adverse Event
22%
Clinical Guideline
15%
Cohort Analysis
15%
Cohort Effect
24%
Colonoscopy
27%
Combination Therapy
31%
Computer Assisted Tomography
20%
Diagnosis
50%
Disease
56%
Duodenum
14%
Endoscopic Ultrasound
15%
Endoscopy
46%
Esophageal Cancer
20%
Fluorodeoxyglucose F 18
20%
Functional Gastrointestinal Disorder
29%
Gastrectomy
16%
Gastroesophageal Reflux
100%
Hazard Ratio
15%
Health Care Cost
19%
Helicobacter
14%
Helicobacter Infection
29%
Helicobacter Pylori
49%
High Risk Population
14%
Infection
15%
Inflammatory Bowel Disease
16%
Injury
25%
Irritable Bowel Syndrome
42%
Jejunum Ulcer
18%
Maintenance Therapy
14%
Meta-Analysis
37%
Neoplasm
29%
Nursing Home
14%
Odds Ratio
15%
Patient Referral
14%
Patient Satisfaction
14%
Patient with Inflammatory Bowel Disease
18%
Population
16%
Positron Emission Tomography
16%
Positron Emission Tomography-Computed Tomography
14%
Prevalence
77%
Proton-Pump Inhibitor
29%
Pylorus
42%
Reflux Esophagitis
53%
Stomach Acid
96%
Stomach Carcinoma
17%
Surgery
22%
Treatment Response
14%
Upper Gastrointestinal Bleeding
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
37%
Abdominal Pain
9%
Acetylsalicylic Acid
11%
Adiponectin
14%
Amoxicillin
10%
Antibiotic Resistance
16%
Anticoagulant Agent
11%
Bleeding
28%
Calcium Sensing Receptor
9%
Cancer Registry
9%
Caustic Agent
9%
Clarithromycin
29%
Colitis
18%
Combination Therapy
35%
Dextran Sulfate
16%
Diarrhea
10%
Digestive System Function Disorder
9%
Disease
41%
Disease Activity
11%
Esomeprazole
9%
Esophagus Cancer
10%
Gastroesophageal Reflux
28%
Gastrointestinal Hemorrhage
10%
Helicobacter Infection
20%
Helicobacter Pylori
46%
Infection
19%
Inflammation
11%
Inflammatory Bowel Disease
23%
Irritable Colon
51%
Jejunum Ulcer
14%
Lansoprazole
15%
Lipopolysaccharide-Induced Inflammation
9%
Macrogol
10%
Noninferiority Trial
11%
Normal Human
14%
Omeprazole
11%
Phase II Trials
9%
Placebo
10%
Potassium Competitive Acid Blocker
19%
Prevalence
63%
Probiotic Agent
11%
Proton Pump Inhibitor
27%
Reflux Esophagitis
31%
Stomach Acid
79%
Stomach Paresis
9%
Syndrome
9%
Tegoprazan
28%
Tiropramide
9%
Tuberculous Pleurisy
9%
Upper Gastrointestinal Bleeding
14%
Nursing and Health Professions
Abdominal Cancer
18%
Antithrombocytic Agent
5%
Ascorbic Acid
9%
Bisacodyl
9%
Bleeding
9%
Bone Density
9%
Chronic Liver Disease
14%
Colonoscopy
9%
Confidence Interval
13%
Constipation
20%
Diagnosis
5%
Digestive System Function Disorder
19%
Disease
15%
Disease Burden
9%
Disease Course
10%
Drug Therapy
12%
Echography
10%
Elderly Patient
9%
Enteropathy
9%
Feces Incontinence
5%
Feeding Tube
6%
Gastroesophageal Reflux
42%
Gastrointestinal Symptom
7%
Hazard Ratio
8%
Hepatitis A
9%
Inflammatory Bowel Disease
11%
Intestine Preparation
9%
Irritable Colon
13%
Laryngopharyngeal Reflux
9%
Macrogol
9%
Odds Ratio
6%
Patient Compliance
9%
Patient Satisfaction
9%
Patient with Gastroesophageal Reflux
10%
Patient with Inflammatory Bowel Disease
10%
Percutaneous Endoscopic Gastrostomy
9%
Practice Guideline
37%
Prevalence
32%
Progesterone Blood Level
9%
Psychometry
9%
Quality of Life
13%
Reflux Esophagitis
7%
Reproducibility
7%
Self Evaluation
14%
Stomach Acid
18%
Surgery
10%
Test Retest Reliability
5%
Treatment Outcome
6%
Walk Test
9%
X Ray Film
9%
